Genzyme hope to “disentangle” Schering Campath deal

Genzyme proposes plan to FTC that will "disentangle" Schering from a marketing agreement for Ilex' leukemia agent Campath, Genzyme Senior VP Thomas DesRosier says. FTC is reviewing Genzyme's proposed $1 bil. acquisition of Ilex and is investigating whether Campath, which is being studied by independent researchers as a transplant treatment, would overlap with Genzyme's renal transplant agent Thymoglobulin (1"The Pink Sheet" May 3, 2004, In Brief). Genzyme expects to reach an agreement in principle with FTC shortly and maintains the deal can be closed this summer...